Literature DB >> 15279071

Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers: a study on-the-field.

A Sartorio1, N Marazzi, F Agosti, G Faglia, C Corradini, E De Palo, S Cella, A Rigamonti, E E Muller.   

Abstract

Seventy-seven Italian eliteathletes(42 M, 35 F, mean age +/- SE: 24.4-0.7 yr, age range: 17-47 yr) of different sport disciplines (sprinters, triathletes, middle-distance runners, road-walkers, cyclists, rowing athletes, skiers, roller hockey players, swimmers) were sampled on-the-field (before a training session) for the determination of basal GH, IGF-I, C-terminal cross-linked telopeptide of type I collagen (ICTP) and amino-terminal propeptide of type III procollagen (PIIINP) levels, two GH-dependent peripheral markers of bone and collagen turnover, respectively. Basal GH concentrations were significantly higher (p<0.001) in female (5.8 +/- 1.0 ng/ml) vs male athletes (1.8 +/- 0.5 ng/ml), with a large spread of values in either gender. Mean GH levels of athletes were significantly higher than those recorded in age-matched sedentary controls (females: 2.5 +/- 0.5 ng/ml, p<0.001; males: 0.5 +/- 0.2 ng/ml, p<0.05). Among female athletes, 7/35 had basal GH values higher than the upper limit of control values (>9.5 ng/ml), while among males 7/42 had values higher than the upper limit of male sedentary controls (>3.6 ng/ml). No significant differences in basal GH concentrations were found between females taking oral contraceptives (OC) and those who did not receive this treatment (5.0 +/- 2.1 vs 6.0 +/- 1.2 ng/ml). IGF-I levels (236.4 +/- 7.8 ng/ml) were in the normal range for age in all athletes (except for 1 athlete with slightly increased levels), no significant correlation being found between GH and IGF-I levels (R2=0.0393). Mean ICTP (4.6 +/- 0.2 ng/ml) and PIIINP (4.4-0.1 ng/ml) concentrations of elite athletes were not significantly different from those recorded in age and matched healthy sedentary subjects; 4 athletes showed increased PIIINP levels and 2 had increased ICTP levels. ICTP and PIIINP levels were positively correlated with chronological age (p<0.001), a positive correlation being also found between the two markers (p<0.001). On the contrary, no significant correlation was found between basal GH/IGF-I levels and ICTP/PIIINP levels. In conclusion, the present study demonstrates that: 1) elite athletes (particularly females), which have frequently increased basal GH on-the-field, have actually normal IGF-I levels; 2) ICTP and PIIINP levels of athletes are similar to those recorded in healthy sedentary, being significantly higher in younger subjects of both groups; 3) the presence of increased basal GH levels, being associated with normal IGF-I, ICTP and PIIINP levels, is probably the result of a transient GH peak in this study group. Further additional studies are requested to verify the possible use of these peripheral GH-dependent markers for detecting exogenous chronic administration of recombinant GH in athletes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15279071     DOI: 10.1007/BF03345283

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  10 in total

1.  Diurnal variations in serum and urine markers of type I and type III collagen turnover in children.

Authors:  O D Wolthers; C Heuck; L Heickendorff
Journal:  Clin Chem       Date:  2001-09       Impact factor: 8.327

2.  Gender-, age-, body composition- and training workload-dependent differences of GH response to a discipline-specific training session in elite athletes: a study on the field.

Authors:  A Sartorio; F Agosti; N Marazzi; L Trecate; G Silvestri; C Lafortuna; M Cappa; E De Palo; G Faglia; C Corradini; S Cella; A Rigamonti; E E Müller
Journal:  J Endocrinol Invest       Date:  2004-02       Impact factor: 4.256

3.  Serum osteocalcin levels in patients with GH deficiency before and during GH treatment.

Authors:  A Sartorio; A Conti; G Guzzaloni; G Faglia
Journal:  Acta Paediatr Scand       Date:  1991-01

4.  A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers.

Authors:  K Brixen; H K Nielsen; L Mosekilde; A Flyvbjerg
Journal:  J Bone Miner Res       Date:  1990-06       Impact factor: 6.741

5.  Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group.

Authors:  S Longobardi; N Keay; C Ehrnborg; A Cittadini; T Rosén; R Dall; M A Boroujerdi; E E Bassett; M L Healy; C Pentecost; J D Wallace; J Powrie; J O Jørgensen; L Saccà
Journal:  J Clin Endocrinol Metab       Date:  2000-04       Impact factor: 5.958

6.  Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.

Authors:  P I Salmela; H Juustila; J Pyhtinen; K Jokinen; M Alavaikko; A Ruokonen
Journal:  J Clin Endocrinol Metab       Date:  1990-04       Impact factor: 5.958

7.  Effects of growth hormone (GH) on plasma bone Gla protein in GH-deficient adults.

Authors:  J S Johansen; S A Pedersen; J O Jørgensen; B J Riis; C Christiansen; J S Christiansen; N E Skakkebaek
Journal:  J Clin Endocrinol Metab       Date:  1990-04       Impact factor: 5.958

8.  New markers of bone and collagen turnover in children and adults with growth hormone deficiency.

Authors:  A Sartorio; A Conti; M Monzani
Journal:  Postgrad Med J       Date:  1993-11       Impact factor: 2.401

9.  The growth hormone/insulin-like growth factor-I axis hormones and bone markers in elite athletes in response to a maximum exercise test.

Authors:  C Ehrnborg; K H W Lange; R Dall; J S Christiansen; P-A Lundberg; R C Baxter; M A Boroujerdi; B-A Bengtsson; M-L Healey; C Pentecost; S Longobardi; R Napoli; T Rosén
Journal:  J Clin Endocrinol Metab       Date:  2003-01       Impact factor: 5.958

10.  Serum type III procollagen propeptide levels in acromegalic patients.

Authors:  G G Verde; I Santi; P Chiodini; R Cozzi; D Dallabonzana; G Oppizzi; A Liuzzi
Journal:  J Clin Endocrinol Metab       Date:  1986-12       Impact factor: 5.958

  10 in total
  2 in total

1.  A follow-up of GH-dependent biomarkers during a 6-month period of the sporting season of male and female athletes.

Authors:  A Sartorio; M Jubeau; F Agosti; N Marazzi; A Rigamonti; E E Müller; N A Maffiuletti
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

2.  Young elite athletes of different sport disciplines present with an increase in pulsatile secretion of growth hormone compared with non-elite athletes and sedentary subjects.

Authors:  G Ubertini; A Grossi; D Colabianchi; R Fiori; C Brufani; C Bizzarri; G Giannone; A E Rigamonti; A Sartorio; E E Muller; M Cappa
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.